Fate Therapeutics names Jamie Harrell to lead commercial development

what happened

GlobeNewswire reported that Fate Therapeutics appointed Jamie Harrell as Senior Vice President, Market Development & Commercial Operations on October 12, 2026. He joined the company’s executive leadership team effective immediately. Harrell has more than 25 years of commercial management experience and has contributed to the launch of more than 25 products, including Lovenox®, Remicade® and Synagis®, each generating more than $1 billion in annual U.S. sales.

At Fate Therapeutics, he will direct market development and commercial planning for the oncology and autoimmune portfolios. The programs include FT819, which is being tested across several autoimmune diseases, including refractory lupus nephritis in the RECLAIM-LN Phase 2 trial, and FT839, under evaluation in a Phase 1/2 basket study covering indications such as rheumatoid arthritis.

Harrell most recently held a marketing and commercial operations leadership post at Aurinia Pharmaceuticals, helping advance the company’s first oral lupus nephritis treatment. Earlier, he served as Chief Commercial Officer at Avalo Therapeutics and led a 350-person commercial organization at Covidien. His previous roles also included senior positions at MedImmune, Centocor, Inc. and Rhone-Poulenc Rorer. He earned a B.S. in Business Administration, with majors in Marketing and Economics, from Samford University.

Fate Therapeutics develops induced pluripotent stem cell-derived cellular immunotherapies for cancer and autoimmune diseases. The company says its off-the-shelf CAR T-cell candidates could be administered in outpatient settings, including community hospitals and physician practices. The release also cautions that statements about the programs’ prospects are forward-looking and depend on clinical results, manufacturing, regulatory approvals and related risks.

why it matters

The appointment expands Fate Therapeutics’ commercial leadership as its clinical programs move toward potential commercialization. Investors will focus on subsequent data for FT819 and FT839, along with the company’s ability to support outpatient delivery of CAR T-cell therapy.

instruments